Updates on Zika Virus Disease
AUTHORS
Kelly R. Klein, MD, FACEP, Associate Professor, Division of Emergency and Global Health, Department of Emergency Medicine, University of Texas Southwestern Medical Center, Dallas.
Paul Moore, MSc, NREMT, Paramedic, Clinical Research Manager, Division of Emergency and Global Health, Department of Emergency Medicine, University of Texas Southwestern Medical Center, Dallas.
PEER REVIEWER
Dean L. Winslow, MD, Professor of Medicine, Division of General Medical Disciplines, Division of Infectious Diseases and Geographic Medicine, Stanford University School of Medicine, CA.
Statement of Financial Disclosure
To reveal any potential bias in this publication, and in accordance with Accreditation Council for Continuing Medical Education guidelines, we disclose that Dr. Farel (CME question reviewer) owns stock in Johnson & Johnson. Ms. Light (nurse planner) reports that she serves as a consultant for Bard Medical. Dr. Schneider (editor), Dr. Stapczynski (editor), Dr. Klein (author), Mr. Moore (author), Dr. Winslow (peer reviewer), Ms. Mark (executive editor), Ms. Coplin (executive editor), and Ms. Hatcher (AHC Media editorial group manager) report no financial relationships with companies related to the field of study covered by this CME activity.
Introduction
Zika virus disease is a global issue. While not technically an emergency, concerned patients will come to our departments seeking advice and diagnostic testing. The economic cost to communities from mosquito-transmitted illnesses is significant but not well studied. In fact, few studies have attempted to assess the true financial consequences to a country or region, making the extrapolation of expenditure to a larger area difficult. Dengue has been studied in nine countries throughout the Americas and Asia, and has an estimated average cost of $500 million up to $1.8 billion per year. That estimate just includes people with disease and their families affected by dengue and does not include prevention and surveillance costs.1 The aim of this article is to discuss the latest recommendations for the prevention of Zika viral disease, the populations and regions still at increased risk, and the latest and most promising research being conducted to develop a Zika virus vaccine and treatment.
Background
Zika virus is a mosquito-borne flavivirus related to the yellow fever, dengue, and West Nile viruses.2 The Zika virus illness is characterized primarily by rash, myalgia, and conjunctivitis and is often self-limiting, with more than 80% of all infected people asymptomatic but still able to transmit the disease. Although news coverage and public interest have waned, it is still an active health concern.
Although new to the western hemisphere, Zika virus first was isolated from the rhesus monkey in the Zika forest in Uganda during surveillance for yellow fever in 1947. The first documented human case of Zika virus was in 1964.3,4 The majority of these first cases were seen in individuals between 20 and 40 years of age, with documented cases in people as young as 4 months old and as old as 98 years. Through the mosquito vector and increased mobility, the virus traveled from Africa across equatorial Asia. In 1997 on the Pacific island of Yap, Zika infected more than 5,000 humans.5 In 2015, Brazil reported the first cases of locally transmitted Zika viral illness in the Americas.6,7 The virus was similar to the strain that caused an epidemic in the South Pacific. The virus likely traveled to Brazil with participants from the Pacific Islands during the Va’a World Sprint Championship canoe race in August 2014.8
In November 2015, the Brazilian Ministry of Health reported a 20-fold increase in the number of cases of neonatal microcephaly in mothers who had been pregnant when they were diagnosed with the Zika viral disease.9,10 In response to the publication by the Brazilian Ministry of Health, the World Health Organization (WHO) declared Zika viral disease a Public Health Emergency of International Concern in February 2016 when it was confirmed that Zika viral illness was the cause of microcephaly in a cluster of newborns. In response, the Centers for Disease Control and Prevention (CDC) released travel precautions, as well as prenatal planning recommendations, for those in areas with reported cases of Zika viral disease, including the United States. Additionally, the CDC published fluid guidelines aimed at U.S. healthcare providers regarding counseling and testing for pregnant women and for those planning pregnancy who might be at risk for Zika virus exposure.11,12 The WHO noted that since 2015, 61 geographic areas have reported Zika virus transmission, with 31 countries reporting fetal and newborn malformations from mothers who were diagnosed with Zika viral illness during their pregnancy.13 (See Figure 1.) During the first four months of 2017, Brazil reported a 95% decrease in cases of diagnosed microcephaly compared to the previous year at the same time and declared its Zika emergency over.
From Jan. 1, 2015 to June 28, 2017, the CDC extrapolated from data reported to ArboNET the following information: U.S. states, 5,359 symptomatic cases reported (5,087 in travelers returning from affected areas); U.S. territories, 36,598 symptomatic Zika virus disease cases (excluding congenital disease cases), with the majority from local mosquito-borne transmission.14 (See Table 1.)
Figure 1. Areas With Risk of Zika
SOURCE: Centers for Disease Control and Prevention
Table 1. Laboratory-confirmed Symptomatic Zika Virus Disease Cases and Presumptive Viremic Blood Donors Reports to ArboNET by States and Territories — United States, 2017
|
|
Symptomatic Disease Cases* (N = 125) |
Presumptive Viremic Blood Donors † (N = 7) |
||
|
States |
No. |
% |
No. |
% |
|
Alabama |
3 |
(2) |
0 |
(0) |
|
Alaska |
1 |
(1) |
0 |
(0) |
|
Arizona |
1 |
(1) |
0 |
(0) |
|
Arkansas |
0 |
(0) |
0 |
(0) |
|
California |
14 |
(11) |
1 |
(14) |
|
Colorado |
3 |
(2) |
0 |
(0) |
|
Connecticut |
0 |
(0) |
0 |
(0) |
|
Delaware |
0 |
(0) |
0 |
(0) |
|
District of Columbia |
0 |
(0) |
0 |
(0) |
|
Florida |
15 |
(12) |
3 |
(43) |
|
Georgia |
1 |
(1) |
0 |
(0) |
|
Hawaii |
1 |
(1) |
0 |
(0) |
|
Idaho |
0 |
(0) |
0 |
(0) |
|
Illinois |
4 |
(3) |
0 |
(0) |
|
Indiana |
1 |
(1) |
0 |
(0) |
|
Iowa |
1 |
(1) |
0 |
(0) |
|
Kansas |
2 |
(2) |
0 |
(0) |
|
Kentucky |
1 |
(1) |
0 |
(0) |
|
Louisiana |
1 |
(1) |
0 |
(0) |
|
Maine |
1 |
(1) |
0 |
(0) |
|
Maryland |
3 |
(2) |
0 |
(0) |
|
Massachusetts |
5 |
(4) |
0 |
(0) |
|
Michigan |
6 |
(5) |
0 |
(0) |
|
Minnesota |
0 |
(0) |
0 |
(0) |
|
Mississippi |
2 |
(2) |
0 |
(0) |
|
Missouri |
1 |
(1) |
0 |
(0) |
|
Montana |
0 |
(0) |
0 |
(0) |
|
Nebraska |
1 |
(1) |
0 |
(0) |
|
Nevada |
0 |
(0) |
0 |
(0) |
|
New Hampshire |
0 |
(0) |
0 |
(0) |
|
New Jersey |
2 |
(2) |
0 |
(0) |
|
New Mexico |
0 |
(0) |
0 |
(0) |
|
New York |
24 |
(19) |
1 |
(14) |
|
North Carolina |
3 |
(2) |
0 |
(0) |
|
North Dakota |
0 |
(0) |
0 |
(0) |
|
Ohio |
3 |
(2) |
0 |
(0) |
|
Oklahoma |
0 |
(0) |
0 |
(0) |
|
Oregon |
1 |
(1) |
0 |
(0) |
|
Pennsylvania |
3 |
(2) |
0 |
(0) |
|
Rhode Island |
2 |
(2) |
0 |
(0) |
|
South Carolina |
0 |
(0) |
0 |
(0) |
|
South Dakota |
0 |
(0) |
0 |
(0) |
|
Tennessee |
0 |
(0) |
0 |
(0) |
|
Texas |
10 |
(8) |
1 |
(14) |
|
Utah |
0 |
(0) |
0 |
(0) |
|
Vermont |
2 |
(2) |
0 |
(0) |
|
Virginia |
3 |
(2) |
0 |
(0) |
|
Washington |
2 |
(2) |
0 |
(0) |
|
West Virginia |
0 |
(0) |
1 |
(14) |
|
Wisconsin |
2 |
(2) |
0 |
(0) |
|
Wyoming |
0 |
(0) |
0 |
(0) |
|
Symptomatic Disease Cases* (N = 502) |
Presumptive Viremic Blood Donors † (N = 3) |
|||
|
Territories |
No. |
(%) |
No. |
(%) |
|
American Samoa |
3 |
(1) |
0 |
(0) |
|
Puerto Rico |
462 |
(92) |
3 |
(100) |
|
U.S. Virgin Islands |
37 |
(7) |
0 |
(0) |
|
Footnotes * Includes reported confirmed and probable Zika virus disease cases per the Council of State and Territorial Epidemiologists (CSTE) case definitions. † Presumptive viremic blood donors are people who reported no symptoms at the time of donating blood, but whose blood tested positive when screened for the presence of Zika virus RNA by the blood collection agency. Some presumptive viremic blood donors develop symptoms after their donation or may have had symptoms in the past. These individuals may be reported as both Zika virus disease cases and presumptive viremic blood donors. SOURCE: From CDC website: https://www.cdc.gov/zika/reporting/2017-case-counts.html. Accessed June 12, 2017. |
||||
Vector and Infection Overview
It is well known that viruses and other diseases spread throughout densely populated communities and during mass migration of populations. The death toll of soldiers and civilians from World War I was dwarfed by the deaths caused by the Spanish flu of 1918. The Spanish flu was caused by a virulent virus transmitted by droplets from infected humans. As with most influenza A viruses, the virus started in animals and, as a result of a major change in the influenza A virus, became a virus with increased morbidity and mortality to a human population with little or no immunity. During World War I, troop deployments on ships, along with large civilian movement, led to spread of the virus. As public health authorities determined how flu was transmitted, they enacted public health laws that stopped the progression of the Spanish flu.
Some viruses, such as the rabies virus, can be avoided because the vector is visible (i.e., dog, raccoon, or bat) or can be prevented through primary vaccination of the host animal. However, insect-transmitted viruses are much harder to control.
The most common vector of insect-transmitted disease is the mosquito, which caused more deaths between the 17th and 20th centuries than all other etiologies of death, including war, combined.15 Initially, mosquito-borne illness was regional and and did not spread widely. However, that changed in the 1940s. Because of large movements of troops and materials, such as tires, mosquitoes and other vectors moved across oceans, allowing infected mosquitoes to spread to other habitats and flourish. Now with continued globalization, these vectors continue to move with ease out of their normal environment.16
The key to controlling mosquitoes and the diseases they transmit is understanding their life cycle and habitat.
Malaria is the most understood of all the mosquito-borne diseases. It is transmitted by a species of the Anopheles mosquito and is said to be the cause of more than 1 million deaths every year. These mosquitoes feed predominantly at dusk and dawn and are found in wet areas.
The West Nile virus now is the No. 1 cause of arboviral meningoencephalitis in the United States. This virus is carried by the Culex mosquito, which feeds mainly at dusk and dawn, and requires stagnant water to breed.
The Aedes mosquito is found in a wide geographic region, and transmits Zika, chikungunya, and dengue.17 While the Culex mosquitoes prefer animals for their blood meal, the Aedes mosquito is a voracious feeder with no diurnal pattern, and preferentially feeds on humans. Additionally, Aedes mosquitoes are adapted to urban living, which includes adjusting to water scarcity, allowing them to breed in small areas of water, such as in window air conditioner units or upturned water bottle caps.18
The life cycle of all mosquitoes is complex, and only three of the stages require water and appropriate temperatures. The stages are as follows:
- Female mosquito lays the eggs in non-flowing water.
- After two to three days at the right temperature, the eggs hatch in the water, becoming larvae.
- From larvae, they develop into pupae (approximately four days).
- The pupae become adults.
The difference between male and female mosquitoes is that males eat nectar and sugars only. On the other hand, the females require blood meals to lay eggs. If conditions are right, the life span of the female is up to three weeks. During this time, she can lay a raft of 100 and 300 eggs every three days if she is able to have a blood meal before each egg deposit.
Control of the Aedes species is more complicated than with other mosquitoes. As mentioned previously, these mosquitoes bite in the daytime and, thus, the normal protection of insecticide-treated bed nets is not effective. Spraying insecticide during the day will indiscriminantly kill other beneficial insects such as pollinating bees. The main method to control the mosquito is to eliminate the breeding habitat. This is done by placing protective covers on containers that have residual water in them, and draining or covering standing water such as in large tanks used to store household water, collections of rain water for drinking or irrigation, used tires, and other items that hold water. Additionally, intensive biological and chemical measures can combat or reduce the Aedes species mosquito population.19 Other methods of control are being investigated. These include releasing sterile male mosquitoes into the population, as well as the use of a synthetic analogue of mosquito juvenile hormones, which prevents the larvae from developing into adults. It is carried by the female mosquito and released onto the eggs when she lays them.20
Virology and Genetics
Zika virus is closely related to the Spondweni virus. Zika is a single-stranded positive RNA virus containing a 10,794 nucleotide genome and two major lineages (African and Asian/American strains).24 Upon transmission, flavivirus virions bind to the surface of target cells by interactions between viral surface glycoproteins and cellular surface receptors (E protein). When they bind, the cell internalizes the virion. Once internalized, the virion uncoats, releasing the viral RNA into the host cell’s cytoplasm.25 Duplication then occurs, the virus particles assemble using the cell’s own endoplasmic reticulum, and they are released from the cell.26 It is theorized that as this cycle repeats, mutations in the Zika RNA will occur, affecting its replication, virulence, and antigenic epitopes, and may cause an overall increase in morbidity and mortality in those who contract the disease.27
Signs and Symptoms
Flaviviruses cause many diseases, with significant differences in pathology. For example, yellow fever, which caused numerous outbreaks for more than 500 years, has a mortality rate up to 20%. It is a hemorrhagic fever with symptoms that include fever, chills, nausea, myalgia, and headache. It may progress to liver, renal, and bleeding diorders.28
Dengue viral disease is transmitted by the Aedes species mosquito and is seen mostly in South and Southeast Asia, but recently migrated to Latin America and the Caribbean. Just as with Zika, most individuals infected with dengue will be asymptomatic. Those who are symptomatic primarily present with high fever, rash, eye pain, myalgia, bleeding, and capillary leaking.
Spondweni virus, the virus most closely related to Zika, is found in sub-Saharan Africa and Papua New Guinea. This virus also is transmitted by infected mosquitoes and is characterized by symptoms of fever, nausea, headaches, malaise, and nosebleeds.29 In regions where both Zika and Spondweni are found, only serologic assay, virus isolation, or detection of viral nucleic acids by polymerase chain reaction (PCR) can distinguish between the two.
In 80% of cases, Zika virus-infected humans are not symptomatic.30,31 Those who become symptomatic complain of rash, fever (> 98.96°F), arthralgia, myalgia, headache, conjunctivitis, retro-orbital eye pain, and fatigue.
It is difficult to diagnose Zika viral illness because the symptoms are similar to the symptoms of dengue and chikungunya viral infections, which are spread by the same mosquitoes that transmit Zika.32,33 Hemorrhagic components are seen in dengue, while Zika infections are associated with neurological symptoms in adults and microcephaly and other congenital disorders in neonates. (See Table 2.)
Table 2. Comparison of Zika, Chikungunya, and Dengue Infectious Signs and Symptoms
|
Characteristic |
Zika |
Chikungunya |
Dengue |
|
Reprinted with permission from: Liu LE, Dehning M, Phipps A, et al. Clinical update on dengue, chikungunya, and Zika: What we know at the time of article submission. Disaster Med Public Health Prep 2016;8:1-10.68-73 |
|||
|
Vector |
Aedes species |
Aedes species |
Aedes species |
|
Endemic Region |
Southern United States, Central/South America, Africa, Asia |
United States (including Alaska), Central/South America, Africa, Asia |
Central/South America, Africa, Asia |
|
Fever |
Low grade |
High grade |
High grade |
|
Incubation Period |
3-7 days |
3-7 days |
4-7 days |
|
Rash |
Maculopapular, erythematous rash |
Pruritic, maculopapular rash, petechial rash (rarer) |
Pruritic petechiae |
|
Other Signs and Symptoms |
Exudative conjunctivitis, myalgia, arthralgia, headache Rare: Guillain-Barré syndrome |
Severe arthralgia (esp. small joints), Gastrointestinal symptoms Rare: myelitis, retinitis, meningoencephalitis, conjunctivitis, epistaxis, subconjunctival hemorrhage |
DHF: Headache, myalgia, DHS: Headach, myalgia, plus extensive hemorrhage, hepatomegaly, third spacing of fluids, shock |
|
Laboratory Findings |
Lymphopenia |
Neutropenia |
Thrombocytopenia, lymphopenia, hypoglycemia, hypocalcaemia, hypernatremia, lactic acidosis, coagulopathy |
|
Diagnosis |
IgM/IgG RT-PCR |
IgM/IgG analysis Viral particle analysis of serum/plasma for virus |
IgM ELISA/IgG RT-PCR |
|
Treatment |
Supportive |
Supportive |
Supportive Avoid NSAIDs with dengue |
|
Effect on Infants via Vertical Transmission |
Possible increased rates of microcephaly, hearing and vision deficits |
Nonspecific viral infection seen in age 3 to 7 days |
Increased rate of LBW infants |
|
Vaccination |
Investigational |
Investigational |
Several, CYD-TDV |
|
Complications |
Mortality rare, possible association with increased rates of microcephaly and Guillain-Barré |
Mortality rare, chronic joint pain |
Mortality rare, more common in those with DHF/DSS |
While dengue and chikungunya are transmitted primarily through the bite of infected mosquitoes and not through human-to-human contact, the Zika virus can be transmitted between humans through saliva, urine, blood, and sexual contact.34,35,36 The discovery of human-to-human spread complicates prevention.
The primary public health significance of the Zika virus is the neurological effects in neonates and adults. The neurological significance of Zika viral disease was appreciated during the outbreak in French Polynesia in 2013-2014. Seventy-four patients presented with neurological symptoms and tested positive for Zika viral disease.37 Guillain-Barré syndrome (GBS), a clinical syndrome of multiple autoimmune idiopathic peripheral neuropathies, most often is seen in adults. The most serious of these complications is a progressive paralysis over a one- to three-week period resulting in a 5% death rate, 20-30% incidence of respiratory failure, and up to 20% of patients left with significant lifelong neurological disability.38,39,40
In the neonatal population, Zika syndrome is a unique pattern of birth defects presenting in fetuses and infants whose mothers were infected with Zika virus during the pregnancy. It is characterized by five significant features that can be diagnosed in utero by ultrasound or at presentation shortly after birth:41
- Severe microcephaly, in which the skull has partially collapsed;
- Decreased brain tissue, with a specific pattern of brain damage, including subcortical calcifications;
- Damage to the back of the eye, including macular scarring and focal pigmentary retinal mottling;
- Congenital contracture, such as clubfoot or arthrogryposis (congenital joint contractures in two or more areas of the body);
- Hypertonia restricting body movement soon after birth.
Diagnosis of Zika Viral Disease
The diagnosis of Zika viral disease by clinical features is challenging in areas where similar-appearing diseases, such as dengue and chikungunya, are prevalent. In adults, Zika viral disease generally presents with rash, fever (> 98.96° F), arthralgia, myalgia, headache, conjunctivitis, retro-orbital pain, and fatigue, which resembles many other viral diseases. Because the symptoms of Zika viral disease are vague and not pathognomonic, serum studies are necessary to confirm diagnosis.
As with many tests, immunoglobulins are used as markers to screen for recent infection (IgM) or history of infection (IgG). Serum tests to screen for the disease have a low sensitivity and specificity, as they cross-react with other flaviviruses, and the IgM will be positive. Serological assays manufactured in Germany and Canada include: Anti-Zika Virus ELISA (IgG/IgM) and IIFT Arborviral Fever Mosadi 2 (IgG/IgM) from Germany, and Zika Virus Rapid Test from Canada.41 These are followed by a more specific test: real-time PCR molecular testing.43 At this time, the U.S. Food and Drug Administration (FDA) has not approved any laboratory tests for the the detection of Zika virus. However, the FDA has issued an Emergency Use Authorization (EUA) for several diagnostic tools for the Zika virus, including the Trioplex Real-Time RT-PCR (rRT-PCR) and the Zika IgM Antibiody Capture Enzyme-Linked Immunosorbent Assay (MAC-ELISA).44
According to recommendations by the CDC and the WHO, if there is a positive IgM ELISA, a plaque reduction neutralization test (PRNT) should be performed for confirmation. This test measures virus-specific neutralizing antibody titers against similar viruses (dengue and chikungunya, for example) and can be used to confirm the Zika virus in the sample.45 (See Table 3.) The Council of State and Territorial Epidemiologists (CSTE) added Zika to the Nationally Notifiable Diseases List, so that IgM Zika or dengue test results that are positive or equivocal must be reported to the local or state health department or authority.46
Table 3. Interpretation of Results of Antibody Testing for Suspected Zika Virus Infection — U.S., 2016 *, †, §, ¶, **
|
Zika Virus and Dengue Virus IgM ELISA |
Zika Virus PRNT |
Dengue Virus PRNT |
Interpretation |
|
Abbreviations: ELISA = enzyme-linked immunosorbent assay; IgM = immunoglobulin M antibodies; PRNT = plaque reduction neutralization test. * For persons with suspected Zika virus disease, Zika virus real-time reverse transcription–polymerase chain reaction (rRT-PCR) should be performed on serum specimens collected < 7 days after onset of symptoms, and on urine specimens collect < 14 days after onset of symptoms. † In the absence of rRT-PCR testing, negative IgM or neutralizing antibody testing in specimens collected < 7 days after illness onset might reflect collection before development of detectable antibodies and does not rule out infection with the virus for which testing was conducted. § Zika IgM positive result is reported as “presumptive positive” to denote the need to perform confirmatory PRNT. ¶ Report any positive or equivocal IgM Zika or dengue results to state or local health department. ** To resolve false-positive results that might be caused by cross-reactivity or nonspecific reactivity, presumptive positive Zika IgM results should be confirmed with PRNT titers against Zika, dengue, and other flaviviruses to which the person might have been exposed. In addition, equivocal and inconclusive results that are not resolved by retesting also should have PRNT titers performed to rule out a false-positive result. Reprinted from: Rabe IB, Staples JE, Villanueva J, et al. Interim Guidance for Interpretation of Zika Virus. Antibody Test Results. MMWR Morb Mortal Wkly Rep 2016;65;543-546. |
|||
|
Positive or equivocal (either assay) |
≥ 10 |
< 10 |
Recent Zika virus infection |
|
Positive or equivocal (either assay) |
< 10 |
≥ 10 |
Recent dengue virus infection |
|
Positive or equivocal (either assay) |
≥ 10 |
≥ 10 |
Recent flavivirus infection; specific virus cannot be identified |
|
Inconclusive in one assay AND inconclusive or negative in the other |
≥ 10 |
< 10 |
Evidence of Zika virus infection; timing cannot be determined |
|
Inconclusive in one assay AND inconclusive or negative in the other |
< 10 |
≥ 10 |
Evidence of dengue virus infection; timing cannot be determined |
|
Inconclusive in one assay AND inconclusive or negative in the other |
≥ 10 |
≥ 10 |
Evidence of flavivirus infection; specific virus and timing cannot be determined |
|
Any result (either or both assays) |
< 10 |
< 10 |
No evidence of Zika virus or dengue virus infection |
|
Positive for Zika virus AND negative for dengue virus |
Not yet performed |
Presumptive recent Zika virus infection |
|
|
Positive for dengue virus AND negative for Zika virus |
Not yet performed |
Presumptive recent dengue virus infection |
|
|
Positive for Zika virus AND positive for dengue virus |
Not yet performed |
Presumptive recent flavivirus virus infection |
|
|
Equivocal (either or both assays) |
Not yet performed |
Equivocal results |
|
|
Inconclusive in one assay AND inconclusive or negative in the other |
Not yet performed |
Inconclusive results |
|
|
Negative for Zika virus AND negative for dengue virus |
Not indicated |
No evidence of recent Zika virus or dengue virus infection |
|
Transmission and Prevention
The most common method of Zika virus transmission is through the bite of an infected Aedes species mosquito. The normal habitat for this mosquito in the United States is the Southeast and Southwest, but it has been found in states as far north as Michigan, New Hampshire, and Washington.7 Preventing mosquito bites is the most effective way of preventing disease transmission. Travelers to endemic countries should wear insect repellent and protective clothing and use mosquito netting that has been sprayed with insecticide. Pregnant women should be discouraged from travel to Zika viral disease endemic countries. If that is not possible, then the CDC recommends the use of repellents that are safer for pregnancy (if used as directed), such as DEET (30%), picardin (20%), and IR3535 (20%) on any exposed skin and on clothing.45
Unlike other mosquito-borne diseases, the Zika virus has other modes of transmission that make preventing the spread of the disease more complicated. For example, during the French Polynesia outbreak, it was noted that 3% of asymptomatic blood donors were positive for acute Zika virus infection. In addition to blood, the Zika virus has been found in semen, saliva, cerebral spinal fluid, and tears. Zika virus also has been found to be transmissable sexually, with women testing positive for Zika viral disease more often than men after having unprotected sexual contact with someone who has traveled recently from a Zika risk area.48,49 Although most of the infections are contracted through the bite of a mosquito, horizontal transmission of the disease from one individual to another is increasing. Additionally, vertical transmission from mother to offspring is well documented, with mother-to-child viral transmission through the placenta or breast milk.36,48
Vaccines
At this time, there are no licensed antiviral drugs to treat Zika disease or vaccines to prevent Zika infection. Research is slow, with one focus on engineering messenger RNAs to attack the E protein on the virus membrane to prevent attachment for the virion to the host cell.51,52,53 Without contact at this site on the cell membrane, the virus cannot be brought into the cell to allow for replication. The creation of neutralizing antibodies directed against the E protein has been effective in protection against other flaviviruses, such as Japanese encephalitis and yellow fever.54
Other vaccines under investigation and testing on humans to combat Zika include inactivated whole virions, live-attenuated recombinant, and DNA vaccines.55 These come with their own potential risks because there is a possibility of triggering the host immune system in unexpected ways. It is unclear which part of the Zika virion causes the autoimmune reaction leading to adverse neurologic outcomes such as Guillain-Barré syndrome or acute myelitis. It is theorized that antibodies that develop after virion exposure to the vaccine also might recognize and target tissues in the human nervous system, thus causing GBS as a side effect of the vaccine.56
Treatment
Currently, no clinically approved therapy is available for the treatment of Zika or any other flavivirus infection.57 Once infection has occurred and the patient is symptomatic, diligent clinical monitoring and supportive care are the mainstays of treatment. Recent studies indicate that Zika, like varicella and other viruses, seems to concentrate in parts of the body that have less immune system vigilance, such as the eyes, placenta, and testes, and can be isolated for months post exposure.7 Caring for patients with severe Zika disease, especially patients exposed in utero, is challenging and requires substantial healthcare and societal resources that strain both families and society. This includes long-term care for infants with Zika syndrome, as well as for adults who need ventilators or other respiratory support for neurological sequelae.
Guidance for Serum Testing
Although most Zika viral infections probably are transmitted by mosquitoes, Zika virus has other modes of transmission, including sexual contact (anal, vaginal, and oral), intrauterine and intrapartum transmission, laboratory exposure, and blood transfusion.58,59,60 Although most viral human-to-human transmissions occur from mildly symptomatic men through unprotected sexual contact with their partners, sexual transmission also has occurred from asymptomatic men and from one male who had a vasectomy.61 Published literature indicates that Zika viral RNA has been isolated in semen at 188 days (approximately six months), with infectious virus reported in semen up to three months.62,63,64
If previously exposed to the Zika virus, women planning to become pregnant should consider Zika IgM testing before conception. This is not to determine if the woman should become pregnant, but rather for use as a comparison to later tests if the patient became exposed during her pregnancy. This then allows for subsequent discussions, testing, and counseling.65
Infants born to mothers with laboratory evidence of the Zika virus detection during pregnancy, and those born with clinical findings suggestive of congenital Zika virus syndrome (microcephaly), should be tested for the virus. The 2017 CDC guidelines for collecting and submitting specimens at the time of birth for Zika virus testing indicate that serum, placenta, fetal membranes, umbilical cord, and infant urine samples should be tested. Since testing standards may change in the future, check local health department guidelines for the most current testing recommendations. (See Figure 2.)
Special Population: Pregnant Women
In the United States, the incidence of pregnant women with laboratory evidence of possible recent Zika virus infection and the number of fetuses/infants with Zika syndrome-associated birth defects is 30 times higher than the baseline of prevalence in the pre-Zika years.66 To help guide healthcare practitioners, the CDC provides recommendations for the screening and testing of pregnant women:
- It is important to ascertain if the patient is at risk for having contracted the Zika virus.
- Did the patient travel to or live in a Zika risk area? (https://www.cdc.gov/zika/geo/countries-territories.html. Accessed June 12, 2017.)
- During pregnancy, did the patient have unprotected sex (vaginal, anal, or oral) with a partner who has traveled to an endemic area of risk?
If the patient has screened positive for the above questions, then:
- Are there any recent signs or symptoms of viral infection?
- If the patient had an ultrasound, were there any abnormalities of the fetus consistent with Zika syndrome?
If the answer is “yes” to either of these secondary questions, the patient should be considered for immunological testing for viral antigens. (See Figure 2.) If the answer is “no” to all of the screening questions, then there is a low risk of Zika virus infection. Patients who are pregnant or planning to get pregnant should be cautioned about travel to Zika virus-prevalent areas. While pregnant, women should use protection during sexual contact with anyone who might have traveled to an at-risk area or who lives in an at-risk area. For patients who have tested positive for Zika virus infection, the CDC recommends serial fetal ultrasounds every three to four weeks to assess fetal anatomy and growth, and discussion of possible amniocentesis.
Figure 2. Testing Guidelines for Pregnant Patients With Possible Zika Exposure
Abbreviations: IgM = immunoglobulin M; PRNT = plaque reduction neutralization test; NAT = nucleic acid testing.
* A pregnant woman is considered symptomatic if one or more signs or symptoms (fever, rash, arthralgia, or conjunctivitis) consistent with Zika virus disease is reported whereas a pregnant woman is considered asymptomatic if symptoms are NOT reported.
† Testing includes Zika virus NAT on serum and urine samples, Zika virus and dengue virus immunoglobulin M (IgM), and plaque reduction neutralization test (PRNT) on serum samples. PRNT results that indicate recent flavivirus infection should be interpreted in the context of the currently circulating flaviviruses. Refer to the laboratory guidance for updated testing recommendations (http://www.cdc.gov/zika/laboratories/lab-guidance.html). Because of the overlap of symptoms in areas where other viral illnesses are endemic, evaluate for possible dengue or chikungunya virus infection.
§ Dengue IgM antibody testing is recommended only for symptomatic pregnant women.
¶ If Zika virus NAT testing is requested from laboratories without IgM antibody testing capacity or a process to forward specimens to another testing laboratory, storing of additional serum samples is recommended for IgM antibody testing in the event of a NAT negative result.
** Possible exposure to Zika virus includes travel to or residence in an area with active Zika virus transmission (http://wwwnc.cdc.gov/travel/notices/), or sex (vaginal sex (penis-to-vagina sex), anal sex (penis-to-anus sex), oral sex (mouth-to-penis sex or mouth-to-vagina sex), and the sharing of sex toys) without a barrier method to prevent infection (male or female condoms for vaginal or anal sex, male condoms for oral sex (mouth-to-penis), and male condoms cut to create a flat barrier or dental dams for oral sex (mouth-to-vagina) with a partner who traveled to or lives in an area with active Zika virus transmission.
SOURCE: Centers for Disease Control and Prevention.
Available at: https://www.cdc.gov/zika/pdfs/zikapreg_screeningtool.pdf
Conclusions
The Zika virus has emerged as a significant health concern for the Americas and continues to be a health concern for Africa and Asia. The virus is spread primarily by the Aedes species mosquito, which is found in many countries, including the United States. Unlike many other mosquito-borne diseases, Zika virus also is transmitted horizontally through sexual contact, blood, and urine, as well as vertically from mother to fetus/newborn, making it more difficult to control locally and allowing spread to non-mosquito areas. Current prevention guidelines recommend that men use condoms or abstain from sex for six months after Zika viral illness, especially with women who are either pregnant, breastfeeding, or of childbearing age to prevent transmission. All pregnant women who have a history of contact with the Zika virus should have an ultrasound to determine any signs of Zika infection sequelae in the fetus. When such abnormalities are present, further testing should be performed to determine if there are Zika antibodies and to discuss the results of the test with the parent to determine the appropriate course of action.
REFERENCES
- Wilder-Smith A, Ooi EE, Vasudevan SG, Gubler DJ. Update on dengue: Epidemiology, virus evolution, antiviral drugs, and vaccine development. Curr Infect Dis Rep 2010;12:157-164.
- Hayes EB. Zika virus outside Africa. Emerg Infect Dis 2009;15:1347-1350.
- Dick GW, Kitchen SF, Haddow AJ. Zika virus. I: Isolations and serological specificity. Trans R Soc Trop Med Hyg 1952;46:509-520.
- Christofferson RC. Zika virus emergency and expansion: Lessons learned from dengue and chikungunya may not provide all the answers. Am J Trop Med Hyg 2016;95:15-18.
- World Health Organization. One year into the Zika outbreak: How an obscure disease became a global health emergency. Available at: http://www.who.int/emergencies/zika-virus/articles/one-year-outbreak/en/index1.html. Accessed July 3, 2017.
- International Society for Infectious Diseases. Zika virus – Brazil: Confirmed. May 15, 2015. Available at: www.promedmail.org/direct.php?id=3370768. Accessed June 6, 2017.
- Fellner C. Zika in America: The year in review. P T 2016;41:778-779.
- Musso D. Zika virus transmission from French Polynesia to Brazil (letter). Emerg Infect Dis 2015;21:1887.
- Kleber de Oliveira W, Cortez-Escalante J, De Oliveira WT, et al. Increase in reported prevalence of microcephaly in infants born to women living in areas with confirmed Zika virus transmission during the first trimester of pregnancy – Brazil, 2015. MMWR Morb Mortal Wkly Rep 2016;65:242-245.
- Rasmussen SA, Jamieson DJ, Honein MA, Petersen LR. Zika virus and birth defects –reviewing the evidence for causality. N Engl J Med 2016;374:1981-1987.
- Oduyebo T, Igbinosa I, Perterson EE, et al. Update: Interim guidance for health care providers caring for pregnant women with possible Zika virus exposure — United States, July 2016. MMWR Morb Mortal Wkly Rep 2016;65:739-744.
- Petersen EE, Staples JE, Meaney-Delman D, et al. Interim guidelines for pregnant women during a Zika virus outbreak- United States, 2016. MMWR Morb Mortal Wkly Rep 2016;65:30-33.
- World Health Organization. Situation Report: Zika Virus, Microcephaly, Guillain-Barré Syndrome. Available at: http://apps.who.int/iris/bitstream/10665/246112/1/zikasitrep-23Jun2016-eng.pdf?ua=1. Accessed June 6, 2017.
- Centers for Disease Control and Prevention. Zika cases in the United States. Available at: https://www.cdc.gov/zika/reporting/case-counts.html. Accessed July 3, 2017.
- Gubler D. Insects in disease transmission. In: Strickland G, ed. Hunter Tropical Medicine, 7th ed. Philadelphia: W.B. Saunders; 1991:981-1000.
- Guber DJ. The changing epidemiology of yellow fever and dengue, 1900 to 2003: Full circle? Comp Immunol Microbiol Infect Dis 2004;27:319-330.
- Kraemer MU, Sinka ME, Duda KA, et al. The global distribution of the arbovirus vectors Aedes aegypti and Ae. albopictus. Elife 2015;4:e08347.
- Tolle MA. Mosquito-borne disease. Curr Probl Pediatr Adolesc Health Care 2009;39:97-140.
- Teixeira MG, Costa Mda C, de Oliveira WK, et al. The epidemic of Zika virus-related microcephaly in Brazil: Detection, control, etiology, and future scenarios. Am J Public Health 2016;106:601-605.
- von Seidlein L, Kekulé AS, Strickman D. Novel vector control approaches: The future for prevention of Zika virus transmission? PLoS Med 2017;14:e1002219.
- Hayes EB. Zika virus outside Africa. Emerg Infect Dis 2009;15:1347-1350.
- Faye O, Freire CC, Iamarino A, et al. Molecular evolution of Zika virus during its emergence in the 20th century. PLoS Negl Trop Dis 2014;8:e2636.
- Malone RW, Homan J, Callahan MV, et al. Zika virus: Medical countermeasure development challenges. PLoS Negl Trop Dis 2016;10:e0004530.
- Saiz JC, Vázquez-Calvo Á, Blázquez AB, et al. Zika virus: The latest newcomer. Front Microbiol 2016;7:496.
- Gollins SW, Porterfield JS. Flavivirus infection enhancement in macrophages: An electron microscopic study of viral cellular entry. J Gen Virol 1985;66:1969-1982.
- Lindenbach BD, Rice CM. Molecular biology of flaviviruses. Adv Virus Res 2003;59:23-61.
- Zhu Z, Chan JF, Tee KM, et al. Comparative genomic analysis of pre-epidemic and epidemic Zika virus strains for virological factors potentially associate with the rapidly expanding epidemic. Emerg Microbes Infect 2016;5:e22.
- Beasley DW, McAuley AJ, Bente DA. Yellow fever virus: Genetic and phenotypic diversity and implications for detection, prevention and therapy. Antiviral Res 2015;115:48-70.
- Chambers TJ, Monath TP. The Flaviviruses: Detection, Diagnosis and Vaccine Development. Academic Press; 2003:376.
- Duffy MR, Chen TH, Hancock WT, et al. Zika virus outbreak on Yap Island, Federated States of Micronesia. N Engl J Med 2009;360:2536–2543.
- Food and Drug Administration. FDA issues recommendations to reduce the risk for Zika virus blood transmission in the United States. Feb. 16, 2016. Available at: www.fda.gov/NewsEvents/Newsroom/PressAnnouncements/ucm486359.htm. Accessed June 6, 2017.
- Fellner C. Zika virus: Anatomy of a global health crisis. P T 2016;41:242-253.
- Plourde AR, BlochEM. A literature review of Zika virus. Emerg Infect Dis 2016;22:1185-1192.
- Foy BD, Kobylinski, KC, Chilson Foy JL, et al. Probable non-vector-borne transmission of Zika virus, Colorado, USA. Emerg Infect Dis 2011;17:880-882.
- Besnard M, Lastère S, Teissier A, et al. Evidence of perinatal transmission of Zika virus, French Polynesia, December 2013 and February 2014. Euro Surveill 2014;19:pii=20751.
- Gourinat AC, O’Connor O, Calvez E, et al. Detection of Zika virus in urine. Emerg Infect Dis 2015;21:84-86.
- Millon P. Épidémiologie des syndromes de Guillain-Barré en Nouvelle-Calédonie entre 2011 et 2014: Influence des arboviroses. Médecine humaine et pathologie 2015. Available at: http://dumas.ccsd.cnrs.fr/dumas-01153577/document. Accessed June 6, 2017.
- van den Berg B, Bunschoten C, van Doorn PA, Jacobs BC. Mortality in Guillain-Barre syndrome. Neurology 2013;80:1650-1654.
- Willison HJ, Jacobs BC, van Doorn PA. Guillain-Barré syndrome. Lancet 2016;388:717-727.
- Smith DW, Mackenzie J. Zika virus and Guillain-Barré syndrome: Another viral cause to add to the list. Lancet 2016;387:1486-1488.
- Centers for Disease Control and Prevention (CDC). Congenital Zika syndrome and other birth defects. Available at: https://www.cdc.gov/zika/hc-providers/infants-children/zika-syndrome-birth-defects.html. Accessed June 12, 2017.
- Fellner C. Zika Virus: Anatomy of a global health crisis. P T 2016;41:242-253.
- Musso D, Gubler DJ. Zika virus. Clin Microbiol Rev 2016;29:487-524.
- Centers for Disease Control and Prevention (CDC). Diagnostic tests for Zika virus. April 2017. Available at: https://www.cdc.gov/zika/hc-providers/types-of-tests.html. Accessed June 11, 2017.
- Rabe IB, Staples JE, Villanueva J, et al. Interim guidance for interpretation of Zika virus antibody test results. MMWR Morb Mortal Wkly Rep 2016;65:543-546.
- Centers for Disease Control and Prevention (CDC). Zika Virus Disease and Zika Virus Infection 2016 Case Definition. Available at: https://wwwn.cdc.gov/nndss/conditions/zika-virus-disease-non-congenital/case-definition/2016/06/. Accessed June 12, 2017.
- Petersen EE, Staples JE, Meaney-Delman D, et al. Interim guidelines for pregnant women during a Zika virus outbreak- United States, 2016. MMWR Morb Mortal Wkly Rep 2016;65:30-33.
- D’Ortenzio E, Matheron S, Yazdanpanah Y, et al. Evidence of sexual transmission of Zika virus. N Engl J Med 2016;374:
2195-2198. - Deckard DT, Chung WM, Brooks JT, et al. Male-to-male sexual transmission of Zika virus — Texas, January 2016. MMWR Morb Mortal Wkly Rep 2016;65:372-374.
- Dupont-Rouzeyrol M, Biron A, O’Connor O, et al. Infectious Zika viral particles in breastmilk. Lancet 2016;387:1051.
- Thomas SJ. Zika virus vaccines — a full field and looking for the closers. N Engl J Med 2017;376:3883-1886.
- Pardi N, Hogan MJ, Pelc RS, et al. Zika virus protection by a single low-dose nucleoside-modified mRNA vaccination. Nature 2017;543:248-251.
- Richner JM, Himansu S, Dowd KA, et al. Modified mRNA vaccines protect against Zika virus infection. Cell 2017;168:1114-1125.
- Plotkin SA. Correlates of protection induced by vaccination. Clin Vaccine Immunol 2010;17:1055-1065.
- Larocca RA, Abbink P, Peron JP, et al. Vaccine protection again Zika virus from Brazil. Nature 2016;536:474-478.
- Maron DF. Zika vaccine could solve one problem while stoking another. Scientific American April 1, 2016. Available at: https://www.scientificamerican.com/article/zika-vaccine-could-solve-one-problem-while-stoking-another/. Accessed June 14, 2017.
- Lim SP, Wang QY, Noble CG, et al. Ten years of dengue drug discovery: Progress and prospects. Antiviral Res 2013;100:500-519.
- Musso D, Nhan T, Robin E, et al. Potential for Zika virus transmission through blood transfusion demonstrated during an outbreak in French Polynesia, November 2013 to February 2014. Euro Surveill 2014;19(14):pii:20761.
- Perez S, Tato R, Cabrera JJ, et al. Confirmed case of Zika virus congenital infection, Spain, March 2016. Euro Surveill 2016;21(24).
- Brooks JT, Friedman A, Kachur RE, et al. Update: Interim Guidance for Prevention of Sexual Transmission of Zika Virus — United States, July 2016. MMWR Morb Mortal Wkly Rep 2016;65:745–747.
- Arsuaga M, Bujalance SG, Díaz-Menéndez M, et al. Probable sexual transmission of Zika virus from a vasectomized man. Lancet Infect Dis 2016;16:1107.
- Barzon L, Pacenti M, Franchin E, et al. Infection dynamics in a traveller with persistent shedding of Zika virus RNA in semen for six months after returning from Haiti to Italy, January 2016. Euro Surveill 2016;21.
- Nicastri E, Castilletti C, Liuzzi G, et al. Persistent detection of Zika virus RNA in semen for six months after symptom onset in a traveller returning from Haiti to Italy, February 2016. Euro Surveill 2016;21.
- Paz-Bailey G, Rosenberg ES, Doyle K, et al. Persistence of Zika virus in body fluids – Preliminary report. N Engl J Med 2017. [Epub ahead of print]
- Centers for Disease Control and Prevention (CDC). CDC updates guidance on interpretation of Zika testing results for pregnant women. May 5, 2017. Available at: https://www.cdc.gov/media/releases/2017/p0505-Zika-testing-results.html. Accessed June 5, 2017.
- Cragan JD, Mai CT, Petersen EE, et al. Baseline prevalence of birth defects associated with congenital Zika virus infection—Massachusetts, North Carolina, and Atlanta, Georgia, 2013–2014. MMWR Morb Mortal Wkly Rep 2017;66:219–222.
- Liu LE, Dehning M, Phipps A, et al. Clinical update on dengue, chikungunya, and Zika: What we know at the time of article submission. Disaster Med Public Health Prep 2016;8:1-10.
- Larocca RA, Abbink P, Peron JP, et al. Vaccine protection again Zika virus from Brazil. Nature 2016;536:474-478.
- National Institute of Allergy and Infectious Diseases. Zika virus vaccines. Available at: https://www.niaid.nih.gov/diseases-conditions/zika-vaccines. Accessed June 11, 2017.
- Roos R. Chikungunya vaccine looks promising in phase 1 trial. Center for Infectious Disease Research and Policy. University of Minnesota. March 2, 2015. Available at: http://www.cidrap.umn.edu/news-perspective/2015/03/chikungunya-vaccine-looks-promising-phase-1-trial. Accessed June 12, 2017.
- Beil L. Vaccines may offer defense against dengue, Zika and chikungunya. ScienceNews June 15, 2016. Available at: https://www.sciencenews.org/article/vaccines-may-offer-defense-against-dengue-zika-and-chikungunya?mode=topic&context=92. Accessed June 11, 2017.
- Guy B, Jackson N. Dengue vaccine: Hypotheses to understand CYD-TDV-induced protection. Nature Rev Microbiol 2016;14:45-54.
- Centers for Disease Control and Prevention. Is it Chikungunya or dengue? Public Information from the CDC. Available at: https://www.cdc.gov/chikungunya/pdfs/Poster_CHIKV_DENV_Comparison_Healthcare_Providers.pdf. Accessed June 12, 2017.
Zika virus disease is a global issue. While not technically an emergency, concerned patients will come to our departments seeking advice and diagnostic testing.
Subscribe Now for Access
You have reached your article limit for the month. We hope you found our articles both enjoyable and insightful. For information on new subscriptions, product trials, alternative billing arrangements or group and site discounts please call 800-688-2421. We look forward to having you as a long-term member of the Relias Media community.